Validation of the Point-Exacct Method in Non-Small Cell Lung Carcinomas (Molecular Diagnostics and Genetics) Validation of the Point-Exacct Method in Non-Small Cell Lung Carcinomas (Molecular Diagnostics and Genetics)

Validation of the Point-Exacct Method in Non-Small Cell Lung Carcinomas (Molecular Diagnostics and Genetics‪)‬

Clinical Chemistry 1998, July, 44, 7

    • 2,99 €
    • 2,99 €

Publisher Description

Point mutations in the Kirsten ras (K-ras) oncogene are one of the most common genetic alterations involved in various types of human cancer (1, 2). In lung cancer, K-ras mutations occur predominantly in codon 12 (3-7). The frequency of those alterations varies within different histological subtypes. K-ras point mutations are found in approximately 15-56% of the adenocarcinomas and to a lesser extent in other types of non-small cell lung carcinomas (NSCLCs) (3, 5, 7-14). The timing of K-ras activation in the process of lung cancer development is still unclear. Both human and animal studies have initially reported that K-ras mutations arise early (15-17), i.e., just before the occurrence of visible tumors. Compared with far more early chromosomal deletions demonstrated in heavy smokers, the K-ras mutation seems to be a late event (18, 19). Several methods have been utilized for the detection of K-ras point mutations in lung cancer. First reports on K-ras point mutation analysis used relatively insensitive methods such as allele-specific oligonucleotide hybridization or direct sequencing of amplification products (3,4,8,10,20-25). At the moment, a number of methods displaying a considerable increase in sensitivity of point mutation detection have been described. Those methods include amplification refractory mutation system (26), allele-specific amplification (27), mismatch amplification mutation assay (28), oligonucleotide ligation assay (29), ligation chain reaction (30), restriction fragment length polymorphism (31), enriched PCR (32), PCR-primer-introduced-restriction analysis with enrichment of mutant alleles (33), PCR-based cloning and hybridization (34), and point mutation detection using exonuclease amplification coupled capture technique (Point-EXACCT) (35, 36). Interestingly, in those studies, the percentage of cases positive for K-ras seemed to be dependent on the sensitivity of the different methods used for point mutation detection.

GENRE
Science & Nature
RELEASED
1998
1 July
LANGUAGE
EN
English
LENGTH
21
Pages
PUBLISHER
American Association for Clinical Chemistry, Inc.
SIZE
200.9
KB

More Books by Clinical Chemistry

D-Dimer Testing for Deep Venous Thrombosis: A Metaanalysis (Clinical Report) D-Dimer Testing for Deep Venous Thrombosis: A Metaanalysis (Clinical Report)
2004
Congenital Analbuminemia Attributable to Compound Heterozygosity for Novel Mutations in the Albumin Gene (Technical Briefs) Congenital Analbuminemia Attributable to Compound Heterozygosity for Novel Mutations in the Albumin Gene (Technical Briefs)
2005
Highly Sensitive Immunoprecipitation Method for Extracting and Concentrating Low-Abundance Proteins from Human Serum (Technical Briefs) Highly Sensitive Immunoprecipitation Method for Extracting and Concentrating Low-Abundance Proteins from Human Serum (Technical Briefs)
2005
Measurement of Pro-C-Type Natriuretic Peptide in Plasma (Technical Briefs) Measurement of Pro-C-Type Natriuretic Peptide in Plasma (Technical Briefs)
2005
Newborn Screening for Lysosomal Storage Disorders (Editorials) Newborn Screening for Lysosomal Storage Disorders (Editorials)
2005
Inadequate Attempts to Measure the Microheterogeneity of Transthyretin by Low-Resolution Mass Spectrometry (Letters) (Letter to the Editor) Inadequate Attempts to Measure the Microheterogeneity of Transthyretin by Low-Resolution Mass Spectrometry (Letters) (Letter to the Editor)
2005